Needham & Company LLC Issues Positive Forecast for Globus Medical (NYSE:GMED) Stock Price

Globus Medical (NYSE:GMED) had its target price raised by Needham & Company LLC from $114.00 to $117.00 in a research report report published on Friday, MarketBeat reports. Needham & Company LLC currently has a buy rating on the medical device company’s stock.

Other equities analysts also recently issued reports about the company. Piper Sandler reaffirmed an “overweight” rating and issued a $115.00 price target (up from $90.00) on shares of Globus Medical in a report on Thursday, January 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Wednesday, April 15th. Wells Fargo & Company upgraded shares of Globus Medical to a “strong-buy” rating in a research report on Wednesday, March 18th. Zacks Research raised shares of Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Finally, Canaccord Genuity Group lifted their price target on shares of Globus Medical from $105.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, January 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $106.36.

Globus Medical Trading Down 8.5%

Globus Medical stock opened at $77.81 on Friday. The company has a fifty day simple moving average of $89.86 and a 200-day simple moving average of $86.65. The stock has a market cap of $10.52 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 1.99 and a beta of 1.00. Globus Medical has a 12-month low of $51.79 and a 12-month high of $101.40.

Globus Medical (NYSE:GMED) last released its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.20. Globus Medical had a return on equity of 13.69% and a net margin of 18.92%.The business had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. During the same period in the prior year, the firm posted $0.68 EPS. The business’s quarterly revenue was up 27.0% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts forecast that Globus Medical will post 4.46 earnings per share for the current fiscal year.

Insider Buying and Selling at Globus Medical

In related news, EVP Kelly Huller sold 20,000 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $94.50, for a total value of $1,890,000.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 18.38% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Sanctuary Advisors LLC grew its position in Globus Medical by 2.3% in the 1st quarter. Sanctuary Advisors LLC now owns 6,611 shares of the medical device company’s stock valued at $570,000 after buying an additional 151 shares during the last quarter. SBI Securities Co. Ltd. raised its position in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Globus Medical by 2.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 6,316 shares of the medical device company’s stock worth $375,000 after acquiring an additional 170 shares during the period. Parallel Advisors LLC lifted its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after acquiring an additional 173 shares during the period. Finally, EverSource Wealth Advisors LLC boosted its holdings in shares of Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares in the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.

Trending Headlines about Globus Medical

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Globus Medical beat Q1 expectations on both earnings and revenue, reporting $1.12 EPS versus $0.92 expected and $759.9 million in sales versus $740.4 million expected; revenue rose 27% year over year and margins improved. Article Title
• Positive Sentiment: The company also raised FY2026 EPS guidance to $4.70-$4.80, above consensus, signaling management confidence in continued growth. Article Title
• Positive Sentiment: Royal Bank of Canada lifted its price target on GMED to $120 from $115 and kept an outperform rating, while Needham raised its target to $117 from $114 and reiterated a buy rating, reflecting bullish analyst sentiment. Article Title
• Neutral Sentiment: Investors are also digesting the company’s Q1 earnings call transcript and related post-earnings coverage, which primarily reinforce the strong results rather than adding new catalysts. Article Title
• Negative Sentiment: Despite the beat and higher guidance, the stock has sold off as traders appear to be taking profits and focusing on expectations that were already elevated going into the report. Article Title

About Globus Medical

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.